Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.41 |
| ▸ | CTSL | P07711 | 9/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | CTSH | P09668 | 1/20 | 0.31 |
| ▸ | CASP4 | P49662 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.31 |
| ▸ | KLK4 | Q9Y5K2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319238 | 0.95 | CTSL (0.44) | CTSSCTSLCTSKCTSBMTOR | |
| Trifluoroacetic Acid SCHEMBL3321529 | 0.94 | CTSS (0.42) | CTSSCTSLCTSKCTSB | |
| Trifluoroacetic Acid SCHEMBL3322739 | 0.91 | CTSL (0.40) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3319215 | 0.89 | CTSL (0.46) | CTSSCTSLCTSKCTSBMTOR | |
| SCHEMBL3315952 | 0.89 | CTSL (0.47) | CTSSCTSLCTSKCTSBMTOR | |
| SCHEMBL3317262 | 0.86 | CTSL (0.43) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3318368 | 0.86 | CTSL (0.43) | CTSSCTSLCTSKCTSB | |
| Trifluoroacetic Acid SCHEMBL3315786 | 0.86 | CTSS (0.37) | CTSSCTSLCTSKCTSBMTOR | |
| SCHEMBL8130329 | 0.84 | MTOR (0.34) | CTSSCTSLCTSKMTOR | |
| Trifluoroacetic Acid SCHEMBL3315643 | 0.83 | CTSS (0.41) | CTSSCTSLCTSKCTSBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | claimed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | CPN1, SERPINB1, PNP | CTSS 37/4885CTSL 31/4885CTSK 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.